Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold

References

• Li H, Liu GG, Wu J, et al. Recent pricing negotiations on innovative medicines pilot in China: experiences, implications, and suggestions. Value Health Regul Issues. 2018;1(15):133–137. doi: 10.1016/j.vhri.2018.01.009
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. PMID: 1306034.
   PubMed Web of Science ®Google Scholar
• Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. PharmacoEconomics. 2010;28(3):175–184. PMID: 20067332 doi: 10.2165/11530650-000000000-00000
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014 Aug 28;371(9):796–797. PMID: 25162885. doi: 10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Kouakou CRC, Poder TG. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. Eur J Health Econ. 2022 Mar;23(2):277–299. Epub 2021 Aug 21. PMID: 34417905. doi: 10.1007/s10198-021-01364-3
   PubMed Web of Science ®Google Scholar
• Bobinac A, Van Exel NJ, Rutten FF, et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010 Dec;13(8):1046–1055. doi: 10.1111/j.1524-4733.2010.00781.x
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. [ Accessed July wever, it has insufficient theoretical ba12, 2022]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
   Google Scholar
• World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). 2005. [cited 2022 Jul 12]. Available from: http://www.who.int/choice/costs/CER_levels/en/
   Google Scholar
• Sun L, Zhou D, Ma A. Measurement of cost effectiveness threshold based on opportunity cost. China J Pharm Econ. 2022;17(3):13–16. doi: 10.12010/j.issn.1673-5846.2022.03.003
   Google Scholar
• Ochalek J, Wang H, Gu Y, et al. Informing a cost-effectiveness threshold for Health technology assessment in China: a marginal productivity approach. PharmacoEconomics. 2020;38(12):1319–1331. doi: 10.1007/s40273-020-00954-y
   PubMed Web of Science ®Google Scholar
• Reckers-Droog V, van Exel J, Brouwer W. Willingness to pay for Health-related quality of life gains in relation to disease severity and the age of patients. Value Health. 2021 Aug;24(8):1182–1192. Epub 2021 Apr 29. PMID: 34372984. doi: 10.1016/j.jval.2021.01.012
   PubMed Web of Science ®Google Scholar
• Zhou T, Li H, Ma A, et al. Study on the threshold of willingness to pay among end-stage patients in pharmacoeconomic evaluation. Health Eco Res. 2018;3:55–57,60. doi: 10.14055/j.cnki.33-1056/f.20180302.006
   Google Scholar
• Chen L, Wang L, Wu J, et al. Discussion on the payment threshold in the economical evaluation of orphan drugs. Chin J Health Policy. 2021;14(11):55–60. doi: 10.3969/j.issn.1674-2982.2021.11.008
   Google Scholar
• Xuan J, Sun W. Consideration of pharmacoeconomic evaluation model and standard of payment threshold for rare diseases in China. J Int Pharm Research. 2019;46(9):659–665. doi: 10.13220/j.cnki.jipr.2019.09.003
   Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23:607–615. doi: 10.1007/s10198-021-01384-z
   PubMed Web of Science ®Google Scholar
• Zhao FL, Yue M, Yang H, et al. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med care. 2011 Mar;49(3):267–272. doi: 10.1097/MLR.0b013e31820192cd
   PubMed Web of Science ®Google Scholar
• Gao L, Xia L, Pan SQ, et al. Health-related quality of life and Willingness to pay per quality-adjusted life-year threshold-A study in patients with epilepsy in China. Value Health Reg Issues. 2015 May;6:89–97. doi: 10.1016/j.vhri.2015.03.019.
   PubMedGoogle Scholar
• Xin Z, Sun L. Considerations of methods for determining cost-effectiveness threshold in China. Chin J New Drugs. 2012;21(24):2857–2860.
   Google Scholar
• Lankarani KB, Ghahramani S, Moradi N, et al. Willingness-to-pay for one quality-adjusted life-year: a population-based study from Iran. Appl Health Econ Health Policy. 2018 Dec;16(6):837–846. PMID: 30123949. doi: 10.1007/s40258-018-0424-4
   PubMed Web of Science ®Google Scholar
• Schurer M, Matthijsse SM, Vossen CY, et al. Varying Willingness to pay based on severity of illness: impact on Health technology assessment outcomes of Inpatient and outpatient drug therapies in the Netherlands. Value Health. 2022 Jan;25(1):91–103. Epub 2021 Dec 1. PMID: 35031104. doi: 10.1016/j.jval.2021.08.003
   PubMed Web of Science ®Google Scholar
• Wolff E, Larsson S, Svensson M. Willingness to pay for Health improvements using stated preferences: prevention versus treatment. Value Health. 2020;23(10):1384–1390. doi: 10.1016/j.jval.2020.06.008
   PubMed Web of Science ®Google Scholar
• Soeteman L, van Exel J, Bobinac A. The impact of the design of payment scales on the willingness to pay for health gains. Eur J Health Econ. 2017;18(6):743–760. doi: 10.1007/s10198-016-0825-y
   PubMed Web of Science ®Google Scholar
• Bauer D, Lakdawalla D, Reif J. Mortality risk, insurance, and the value of life. NBER Working Papers, National Bureau of Economic Research, Inc. 2018, 25055. doi:10.3386/W25055.
   Google Scholar
• Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care. 1986;14(3–4):172–174. doi: 10.1111/j.1748-720x.1986.tb00974.x
   PubMedGoogle Scholar
• McKie J, Richardson J. The rule of rescue. Soc Sci Med. 2003 Jun;56(12):2407–2419. doi: 10.1016/s0277-9536(02)00244-7
   PubMed Web of Science ®Google Scholar
• Svensson M, Nilsson F, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of cost-effectiveness and disease severity. PharmacoEconomics. 2015 Jun;33(11):1229–1236. doi: 10.1007/s40273-015-0307-6
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Allocation. 2013 Sep;11(12):1–7. doi: 10.1186/1478-7547-11-22
   PubMedGoogle Scholar
• Nimdet K, Chaiyakunapruk N, Vichansavakul K, et al. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760
   PubMed Web of Science ®Google Scholar
• Sund B, Svensson M. Estimating a constant WTP for a QALY-a mission impossible? Eur J Health Econ. 2018 Jul;19(6):871–880. doi: 10.1007/s10198-017-0929-z
   PubMed Web of Science ®Google Scholar
• de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513. doi: 10.1056/NEJMoa1911793
   PubMed Web of Science ®Google Scholar
• Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK age trial): final results of a randomised, controlled trial. Lancet Oncol. 2020 Sep;21(9):1165–1172. doi: 10.1016/S1470-2045(20)30398-3
   PubMed Web of Science ®Google Scholar
• Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med. 2022 Oct 27;387(17):1547–1556. doi: 10.1056/NEJMoa2208375
   PubMed Web of Science ®Google Scholar
• He Z, Liu Z, Liu M, et al. Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. Gut. 2019 Feb;68(2):198–206. doi: 10.1136/gutjnl-2017-315520
   PubMed Web of Science ®Google Scholar
• Porras C, Tsang SH, Herrero R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial. Lancet Oncol. 2020 Dec;21(12):1643–1652. doi: 10.1016/S1470-2045(20)30524-6
   PubMed Web of Science ®Google Scholar
• Stadhouders N, Koolman X, van Dijk C, et al. The marginal benefits of healthcare spending in the Netherlands: estimating cost-effectiveness thresholds using a translog production function. Health Econ. 2019;28(11):1331–1344. doi: 10.1002/hec.3946
   PubMed Web of Science ®Google Scholar
• van Baal P, Perry-Duxbury M, Bakx P, et al. A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2019 Jan;28(1):87–100. doi: 10.1002/hec.3831
   PubMed Web of Science ®Google Scholar
• Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020 Jun 1;35(5):546–555. doi: 10.1093/heapol/czz152
   PubMed Web of Science ®Google Scholar
• Edney LC, Haji Ali Afzali H, Cheng TC, et al. Estimating the reference incremental cost-effectiveness ratio for the Australian Health system. PharmacoEconomics. 2018 Feb;36(2):239–252. doi: 10.1007/s40273-017-0585-2
   PubMed Web of Science ®Google Scholar
• Safari H, Poder TG, Afshari S, et al. Determination of a cost-effectiveness threshold for cancer interventions in Iran. Front Oncol. 2022 Dec 12;12:1039589. doi: 10.3389/fonc.2022.1039589
   PubMed Web of Science ®Google Scholar
• Vanness DJ, Lomas J, Ahn H. A Health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021 Jan;174(1):25–32. doi: 10.7326/M20-1392
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness —the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi: 10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Edney LC, et al. Are estimates of the Health opportunity cost being used to draw conclusions in published cost-effectiveness analyses? A scoping review in four countries. Appl Health Econ Health Policy. 2022 May;20(3):337–349. doi: 10.1007/s40258-021-00707-8
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
   Google Scholar